as 3201 has been researched along with Diabetic Neuropathies in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, T; Inoue, K; Ishii, D; Itou, M; Kakuyama, H; Takagaki, T; Uchida, N | 1 |
| Baba, M; Hamatani, T; Imai, T; Kohara, N; Komori, T; Naito, Y; Satoh, J; Sekiguchi, K; Yamaguchi, Y | 1 |
| Giannoukakis, N | 1 |
| Arezzo, J; Bradshaw, KL; Bril, V; Gordon, RJ; Junor, RW; Nash, M; Polydefkis, M; Shaibani, A | 1 |
| Kohara, N; Satoh, J; Sekiguchi, K; Yamaguchi, Y | 1 |
| Bril, V; Kuromiya, A; Matsumoto, T; Ono, Y; Toyosawa, K; Ueda, Y | 1 |
| Bril, V; Kuromiya, A; Kurono, M; Matsumoto, T; Nakamura, K; Ono, Y | 1 |
| Bril, V; Buchanan, R; Hirose, T; Tomioka, S | 1 |
| Bril, V; Buchanan, RA | 2 |
1 review(s) available for as 3201 and Diabetic Neuropathies
| Article | Year |
|---|---|
Evaluation of ranirestat for the treatment of diabetic neuropathy.
Topics: Aldehyde Reductase; Animals; Biomarkers; Clinical Trials as Topic; Diabetic Neuropathies; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Mice; Pyrazines; Rats; Reproducibility of Results; Spiro Compounds | 2014 |
7 trial(s) available for as 3201 and Diabetic Neuropathies
| Article | Year |
|---|---|
Pharmacokinetics and Safety of Ranirestat in Patients With Hepatic Impairment.
Topics: Adult; Aged; Area Under Curve; Diabetic Neuropathies; Enzyme Inhibitors; Female; Healthy Volunteers; Humans; Liver Diseases; Male; Middle Aged; Protein Binding; Pyrazines; Spiro Compounds | 2020 |
Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
Topics: Adult; Aged; Aldehyde Reductase; Diabetic Neuropathies; Double-Blind Method; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Neural Conduction; Prognosis; Pyrazines; Quality of Life; Spiro Compounds; Young Adult | 2019 |
Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.
Topics: Aged; Diabetic Neuropathies; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Neural Conduction; Polyneuropathies; Pyrazines; Quality of Life; Spiro Compounds; Treatment Outcome | 2015 |
Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study.
Topics: Administration, Oral; Aged; Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Japan; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Motor Neurons; Neural Conduction; Pyrazines; Sensory Receptor Cells; Severity of Illness Index; Spiro Compounds; Temperature | 2016 |
Ranirestat for the management of diabetic sensorimotor polyneuropathy.
Topics: Adolescent; Adult; Aged; Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Median Nerve; Middle Aged; Motor Neurons; Neural Conduction; Placebos; Pyrazines; Sensory Thresholds; Spiro Compounds; Sural Nerve; Young Adult | 2009 |
Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy.
Topics: Adolescent; Adult; Aged; Aldehyde Reductase; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electromyography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neural Conduction; Polyneuropathies; Probability; Pyrazines; Reference Values; Risk Assessment; Severity of Illness Index; Spiro Compounds; Sural Nerve; Treatment Outcome | 2004 |
Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
Topics: Aldehyde Reductase; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Enzyme Inhibitors; Glycated Hemoglobin; Humans; Motor Neurons; Neural Conduction; Patient Selection; Peripheral Nerves; Peroneal Nerve; Placebos; Pyrazines; Spiro Compounds; Sural Nerve | 2006 |
2 other study(ies) available for as 3201 and Diabetic Neuropathies
| Article | Year |
|---|---|
Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy and cataract formation in rats.
Topics: Aldehyde Reductase; Animals; Cataract; Diabetic Neuropathies; Enzyme Inhibitors; Pyrazines; Rats; Spiro Compounds | 2008 |
Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats.
Topics: Aldehyde Reductase; Animals; Diabetes Mellitus; Diabetic Neuropathies; Enzyme Inhibitors; Male; Neural Conduction; Pyrazines; Rats; Rats, Wistar; Sorbitol; Spiro Compounds; Streptozocin | 2008 |